Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

161results about How to "Avoid sudden release" patented technology

Core-shell type pre-charged chemotherapy medicine embolization microsphere and preparation method thereof

The invention provides a core-shell type pre-charged chemotherapy medicine embolization microsphere and a preparation method thereof. The method comprises the following steps of using water/oil/water(W/O/W) complex emulsion type or oil/water/oil (O/W/O) complex emulsion type emulsified micro liquid drips as templates; coating tiny liquid drips containing medicine into outer layer liquid drips; high molecular polymers in the inner and outer layer liquid drips are converted through measures such as physical measures and chemical measures to form an inner layer core and an outer layer shell. Theformed core-shell structure medicine microsphere is formed by polymers of two-layer structures; the inner core contains medicine; the outer shell is favorable for maintaining the activity of the inner core medicine; the stable medicine release is realized; the sudden release is prevented; the safety is enhanced. The medicine carried microsphere prepared by the method has the advantages that the particle diameter range is 10 to 1000 micrometers; the sphere degree is good; the particle diameter is uniform; (the dimension deviation is 5 percent); the medicine encapsulation rate is high; the structure/carried medicine is controllable; meanwhile, the preparation method of the pre-charged chemotherapy medicine embolization microsphere can provide a novel idea for the clinic application study ofthe transcatheter arterial embolization.
Owner:ENERGY RES INST OF SHANDONG ACAD OF SCI

Cholesterol modified amphiphilic pH response pennicuius copolymer as well as preparation and micelle of copolymer

The invention belongs to the technical field of preparation of biomedical high molecular polymer materials and discloses a cholesterol modified amphiphilic pH response pennicuius copolymer and a preparation method and a micelle system prepared based thereof. The copolymer has a structure shown in the formula I in the specification, wherein x is 10-36, y is 15-40 and z is 8-30. The copolymer is obtained by virtue of irregular copolymerization of a hydrophilic block hydroxyethyl methylacrylate, hydrophobic cholesterol and pH response block methacrylic acid N, N-diethyl aminoethyl combined with hydrophilic poly(ethylene glycol) methyl ether methacrylate. The copolymer is dissolved in a solvent to obtain a nanoscale micelle system, wherein the inner layer is a cholesterol modified hydrophobic chain segment, the middle layer is a pH response chain segment and the shell is a hydrophilic chain segment, so that the function of high entrapment performance, stable existence of a neutral condition and quick release in a weak acidic condition is achieved. By adjusting the proportions of the blocks in the polymer, the release rates of medicines can be regulated to satisfy the release requirements on different drugs.
Owner:SOUTH CHINA UNIV OF TECH

Water-retention and slow-release fertilizer based on coal gangue micron-grade hollow sphere and preparation method of fertilizer

InactiveCN103570463APromote sustainable developmentLarge drug loading capacity in the cavityFertilizer mixturesOrganic fertilizerMaterials science
The invention discloses water-retention and slow-release fertilizer based on a coal gangue micron-grade hollow sphere and a preparation method of the fertilizer. The novel water-retention and slow-release fertilizer based on the coal gangue micron-grade hollow sphere consists of a coal gangue hollow sphere shell layer and a fertilizer core layer, wherein the shell layer is a coal gangue micron-grade hollow sphere or a coal gangue micron-grade hollow sphere coated with an organic coating material on the surface, and the core layer consists of a fertilizer material or a composite material simultaneously containing organic fertilizer and a water-retention material. The material of the core layer is dissolved in water, and is loaded in a hollow cavity of the coal gangue hollow sphere through vacuum, ultrasonic or pressurized impregnation; and the organic coating material covers the coal gangue hollow sphere to seal a shell porous structure, so as to enhance a slow-release effect. The water-retention and slow-release fertilizer disclosed by the invention obviously enhances slow-release performance of the fertilizer, improves utilization rate of the fertilizer and makes full use of solid waste coal gangue, and has relatively strong water-absorption and water-retention properties; and the fertilizer is low in cost, simple in process and environment-friendly and has wide application prospect.
Owner:TSINGHUA UNIV

Doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel and preparation method thereof

The invention relates to a doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel and a preparation method thereof. The doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel comprises chitosan, sodium beta-glycerophosphate, and polyethylene glycol with two ends respectively carrying a benzaldehyde group. The preparation method comprises the following steps: forming an imide bond with a self-healing performance through using a reaction of an amino group in the structure of chitosan and the benzaldehyde groups at two ends of the polyethylene glycol, combining the imide bond with chitosan / sodium beta-glycerophosphate temperature-sensitive gel, and loading doxorubicin hydrochloride into the obtained material through physical clathration to prepare the novel temperature-sensitive self-healing hydrogel administration system. The administration system is a liquid at room temperature, and rapidly gelates at a human body temperature after being injected to a tumor position in order to form a medicine reservoir ; and compared with traditional in situ gels, the temperature-sensitive self-healing hydrogel has the advantages of strong mechanical strength, realization of rapid self restoration under the action of outside force or tissue damages to avoid burst release of a medicine, further delay of release of the medicine and prolongation of the detention time of the medicine in the tumor position, medicine effect enhancement and reduction of toxic and side effects.
Owner:CHINA PHARM UNIV

Manufacturing method for flexible display screen and preparing device for flexible display screen

The invention, which is suitable for the technical field of the flexible display screen, discloses a manufacturing method for a flexible display screen and a preparing device for a flexible display screen. The manufacturing method comprises: preparing a carrier substrate and a stripping device; setting a stripping separation layer on the carrier substrate; arranging a flexible display screen layer on the stripping separation layer; arranging a support membrane adhering to the flexible display screen layer on the surface of the stripping device; and driving the stripping device, enabling the support membrane to adhering to the flexible display screen layer, and stripping the flexible display screen layer from the stripping separation layer. In addition, the preparing device consists of a stripping device and a flexible display screen layer forming component for forming a flexible display screen layer on a stripping separation layer; and a support membrane that adheres to the flexible display screen layer to strip the flexible display screen layer from the stripping separation layer is arranged on the surface of the stripping device. According to the invention, non-destructive stripping is realized; the product yield is high; the performances are excellent; and the cost is low.
Owner:TCL CORPORATION

Microsphere preparation encapsulating hydrophilic medicine and preparation method thereof

The invention discloses a microsphere preparation encapsulating a hydrophilic medicine, and the microsphere preparation comprises the following components in percentage by weight: a hydrophilic medicine 0.1-40%, methoxy poly(ethylene glycol)-poly(lactic acid) block copolymers 0.1-99%, and poly(lactic acid) or poly(lactic acid-glycollic acid) copolymers 0.1-99%. The microsphere preparation has round and intact surface, uniform and controllable particle diameter, high encapsulation rate, and controllable drug release behaviors. The invention also discloses a preparation method of the microsphere preparation encapsulating the hydrophilic medicine, and the preparation method has simple process and good controllability and comprises the following steps: adding a water solution of the hydrophilic medicine into an organic solution of the methoxy poly(ethylene glycol)-poly(lactic acid) block copolymers, and vortexing to form water-in-oil type primary emulsion; adding the primary emulsion intoliquid paraffin containing emulsifier I, and vortexing to form water-in-oil type multiple emulsion; and adding the multiple emulsion into liquid paraffin containing emulsifier II, continuing stirringfor 4-24 h, centrifuging, collecting pellets, washing, and drying to obtain the microsphere preparation encapsulating the hydrophilic medicine.
Owner:ZHEJIANG UNIV

Adriamycin nano-particles and preparation method thereof

The invention provides adriamycin nano-particles. The adriamycin nano-particles are prepared by compounding adriamycin and a block copolymer with a structure shown as a formula (I) or a formula (II) through electrostatic interaction. A preparation method for the adriamycin nano-particles comprises the following step of: electrostatically compounding the adriamycin and the block copolymer with thestructure shown as the formula (I) or the formula (II) in an aqueous medium to obtain the adriamycin nano-particles. In the aqueous medium, a poly(gamma-propargyl-L-glutamate-g-mercaptosuccinic acid)segment and a polyethylene glycol segment which are contained in the block copolymer wrap the adriamycin into cores of the nano-particles, so the adriamycin composite particles are high in stability.The nano-particles are expected to be gathered at tumor sites in blood circulation through an 'enhanced permeability and retention effect' so as to improve the targeting effect of the adriamycin on the tumor sites. Meanwhile, the electrostatic interaction between a carboxyl group of the block copolymer and an amino group of the adriamycin is easy to eliminate under the condition of low intracellular pH values, so that the intracellular release can be accelerated, and the medicinal effect can be improved.
Owner:CHANGZHOU INST OF ENERGY STORAGE MATERIALS &DEVICES

Acipimox film-controlled slow-release pellet capsule

The invention relates to an acipimox film-controlled slow-release pellet capsule. A slow-release film of the acipimox film-controlled slow-release pellet utilizes Eurdragit NE 30D as a film-formation material. A pellet core of the acipimox film-controlled slow-release pellet contains low-substituted hydroxypropyl cellulose having high expansibility, and also contains pharmaceutically acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose and lactose, and the pellet core comprises 10 to 40wt% of the low-substituted hydroxypropyl cellulose. The slow-release film comprises the Eurdragit NE 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit NE 30D to triethyl citrate to talcum powder is 30: 2: 4 and coating weight gain is in a range of 20 to 39%. The acipimox film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxypropyl cellulose having high water expansibility and thus after absorbing water, the acipimox film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the acipimox film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept prior to expiration date.
Owner:北京天衡药物研究院有限公司

Preparation method of high-strength self-healing hydrogel

The invention discloses a preparation method of high-strength self-healing hydrogel and belongs to the technical field of preparation of medical materials. The preparation method comprises the following steps: dissolving polyvinyl alcohol, adding an acrylamide solution, by taking N,N'-methylene bisacrylamide as a crosslinking agent and nano titanium dioxide as a free radical initiator, firstly polymerizing acrylamide under ultraviolet light condition to form polyacrylamide network gel, then carrying out freeze-thraw cycle to form polyvinyl alcohol network gel, then carrying out oxidation crosslinking on the surface of a prefabricated hydrogel network by utilizing self-polymerization effect of dopamine, so that a polydopamine composite layer strongly adhered on the surface of a gel network is formed, and self-made nano hydroxy calcium phosphate is adsorbed, and the aim of further strengthening the hydrogel network is achieved. Meanwhile, the formed polydopamine surface layer and the adsorbed nano hydroxy calcium phosphate have good biocompatibility, and the problem that the traditional self-healing hydrogel is poor in mechanical strength and biocompatibility is effectively solved, so that the high-strength self-healing hydrogel has better application prospect.
Owner:CHANGZHOU YAHUAN ENVIRONMENTAL PROTECTION TECH

Isosorbide mononitrate sustained-release pellet, and isosorbide mononitrate quick-release and sustained-release pellet capsule adopting it

The invention relates to an isosorbide mononitrate sustained-release pellet, and an isosorbide mononitrate quick-release and sustained-release pellet capsule adopting it. The sustained-release film of the sustained-release pellet adopts Eurdragit RS 30D as a film forming material, the core of the sustained-release pellet contains high-expansibility sodium carboxymethyl starch and a pharmaceutically-acceptable excipient commonly used for sustained-release pellets, and optimally, the excipient is microcrystalline cellulose, wherein the weight percentage of sodium carboxymethyl starch in the core of the sustained-release pellet is 5-20%. The sustained-release film of the sustained-release pellet includes the Eurdragit RS 30D, a plasticizer triethyl citrate and an anti-adherent talcum powder, the optimal ratio of the Eurdragit RS 30D to triethyl citrate to the talcum powder is 30:3:4, and the optimal coating weight gain is 19-38%. The core will obviously expand after absorbing water because of the containment of sodium carboxymethyl starch highly expanding after contacting with water, so the sustained-release film is stretched, the thickness of the film is thinned, the apertures of water-pervious micro-pores are increased, the permeability is good, and the permeability decrease caused by film ageing is compensated, thereby the middle and later stage release speed is basically constant, the last stage residue is small, and a stable release performance is always maintained prior to the expiration date.
Owner:北京天衡药物研究院有限公司

Manually operated rotative locking device for orthopedic orthoses or braces

A blocking device (20) for fastening orthoses used in the orthopedic-rehabilitation sector to parts of the body of a person comprises a casing (21) housing a cable (40) wound on a reel (23) by the rotation of a knob (27) restrained to the casing (21) during the winding stage and partially releasable from the casing by pushing and / or pulling the knob, in order to operate with respect to a ratchet-type non-return system, wherein the ratchet-type non-return system consists of elastic tabs (32) which are part of the casing (21), and an inner toothed edge (31) of the knob (27). The knob (27) is restrained in a rotating direction and unrestrained in an axial direction with respect to the reel (23) by a pin (25) with a shaped head (25′), whereby the restraint between the knob (27) and the reel is achieved by a shaped axial opening (30) in the knob, which reflects the shape of the head (25′) of the pin (25), wherein maintaining the knob (27) in the gripping / release positions is ensured by the concave profiles (33) present on the shaped head (25′) of the pin (25) and convex surfaces (34) present in the opening (30) of the knob (27), thereby allowing the knob to be moved from a gripping condition with the ratchet-type non-return system in the tightening and blocking stage to a release condition in the opening stage while maintaining control of the cable (40) wound on the reel.
Owner:F G P

Choline fenofibrate film-controlled enteric slow-release pellet capsule

The invention relates to a choline fenofibrate film-controlled enteric slow-release pellet capsule. A slow-release film of the choline fenofibrate film-controlled enteric slow-release pellet utilizes Eurdragit RS 30D as a film-formation material. A pellet core of the choline fenofibrate film-controlled enteric slow-release pellet contains low-substituted hydroxypropyl cellulose having high expansibility, and also contains a pharmaceutically acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of the low-substituted hydroxypropyl cellulose. The slow-release film comprises Eurdragit RS 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of urdragit RS 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 20 to 38%. The choline fenofibrate film-controlled enteric slow-release pellet comprises the pellet core containing low-substituted hydroxypropyl cellulose having high water expansibility and thus after absorbing water, the choline fenofibrate film-controlled enteric slow-release pellet expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the choline fenofibrate film-controlled enteric slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
Owner:北京天衡药物研究院有限公司

Preparation method of medical antibacterial bandage

The invention discloses a preparation method of a medical antibacterial bandage. The preparation method comprises spinning, weaving of a blank towel, preparation of an antibacterial liquid, preparation of an antibacterial soaking liquid, modification treatment, softening and drying. The modification treatment process comprises dipping a blank towel obtained by the step b into a washing machine, carrying out cleaning through water at 95-100 DEG C according to a bath ratio of 1: 20-27 for 25-36min, cooling the blank towel to 5-10 DEG C, washing the blank towel through water for 4-8min, adding anantibacterial soaking solution into the water, adjusting the temperature of the water solution to 65-75 DEG C, and carrying out soaking through the washing machine for 40-50min. The drying process comprises taking out a bandage and carrying out freeze drying to obtain gel on the surface of the bandage. The invention provides the preparation method of the medical antibacterial bandage. The medicalantibacterial bandage has the traditional sterilization and antibacterial functions and a cleaning function, has effects of improving blood circulation, promoting metabolism, eliminating fatigue andrefreshing brain, feels smooth, supple and comfortable, absorbs moisture and is breathable and comfortable.
Owner:JIANGSU GOLDEN AUTUMN ELASTIC FABRICS

Venlafaxine hydrochloride film-controlled slow-release pellet capsule

The invention relates to a venlafaxine hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the venlafaxine hydrochloride film-controlled slow-release pellet utilizes Kollicoat SR30D as a film-formation material. A pellet core of the venlafaxine hydrochloride film-controlled slow-release pellet contains low-substituted hydroxyprepyl cellulose having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of low-substituted hydroxyprepyl cellulose. The slow-release film comprises Kollicoat SR30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Kollicoat SR30D to triethyl citrate to talcum powder is 30: 1: 4 and a film weight increasing ratio is in a range of 21 to 39%. The venlafaxine hydrochloride film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxyprepyl cellulose having high water expansibility and thus after absorbing water, the venlafaxine hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the venlafaxine hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
Owner:北京天衡药物研究院有限公司

Glipizide film-controlled slow-release pellet capsule

The invention relates to a glipizide film-controlled slow-release pellet capsule. A slow-release film of the glipizide film-controlled slow-release pellet utilizes Eurdragit RL 30D as a film-formation material. A pellet core of the glipizide film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose, lactose and sodium dodecyl sulfate, and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit RL 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 17 to 36%. The glipizide film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the glipizide film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the glipizide film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
Owner:内蒙古天衡医院管理有限公司

Ambroxol hydrochloride film-controlled slow-release pellet capsule

The invention relates to an ambroxol hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the ambroxol hydrochloride film-controlled slow-release pellet utilizes Kollicoat SR 30D as a film-formation material. A pellet core of the ambroxol hydrochloride film-controlled slow-release pellet contains low-substituted hydroxyprepyl cellulose having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose and lactose, and the pellet core comprises 10 to 40wt% of low-substituted hydroxyprepyl cellulose. The slow-release film comprises Kollicoat SR 30D, triethyl citrate as a plasticizer, and talcum powder as an antiplastering aid, wherein preferably, a ratio of Kollicoat SR 30D to triethyl citrate to talcum powder is 30: 1.5: 4 and a film weight increasing ratio is in a range of 20 to 36%. The ambroxol hydrochloride film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxyprepyl cellulose having high water expansibility and thus after absorbing water, the ambroxol hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the ambroxol hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
Owner:北京天衡药物研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products